| Market Capitalization (Millions $) |
129 |
| Shares
Outstanding (Millions) |
125 |
| Employees |
38 |
| Revenues (TTM) (Millions $) |
2 |
| Net Income (TTM) (Millions $) |
-84 |
| Cash Flow (TTM) (Millions $) |
29 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Milestone Pharmaceuticals Inc. is a research-driven biopharmaceutical company that focuses on developing and commercializing novel therapies for cardiovascular and metabolic diseases. The company is based in Montreal, Canada and was founded in 200
Milestone Pharmaceuticals Inc. is primarily focused on developing drugs that target cardiovascular and metabolic disorders, including hypertension, atrial fibrillation, and heart failure. The company's lead product candidate is called etripamil, which is a calcium channel blocker that is delivered through a nasal spray. Etripamil is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), which is a type of arrhythmia that affects the heartes upper chambers.
Milestone Pharmaceuticals Inc. has conducted several clinical trials to investigate etripamil's efficacy and safety. These studies have demonstrated that etripamil can rapidly terminate PSVT and help prevent its recurrence. In addition, etripamil has been found to be safe, well-tolerated, and effective in patients with normal cardiac function.
In addition to etripamil, Milestone Pharmaceuticals Inc. is also working on developing other drug candidates for the treatment of cardiovascular and metabolic disorders. The company's pipeline includes medications targeting hypertension, atrial fibrillation, and heart failure.
Milestone Pharmaceuticals Inc. has received substantial funding from a number of sources, including venture capital firms, strategic partners, and government grants. The company has also received orphan drug designation from the United States Food and Drug Administration (FDA) for etripamil, which provides incentives for the development of drugs that treat rare diseases.
Overall, Milestone Pharmaceuticals Inc. is a highly innovative biopharmaceutical company that is dedicated to developing novel therapies for the treatment of cardiovascular and metabolic disorders. The company's focus on developing targeted therapies that address unmet medical needs, combined with its robust clinical development program, positions it as a leader in this field.
Company Address: 1111 Dr. Frederik-Philips Boulevard Montréal 0 QC
Company Phone Number: 336-0444 Stock Exchange / Ticker: NASDAQ MIST
|
0.13% 
142.58 %